Contains Nonbinding Recommendations

Draft – Not for Implementation

Draft Guidance on Lutetium Lu-177 Vipivotide Tetraxetan

August 2023

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

Active Ingredient: Lutetium Lu-177 vipivotide tetraxetan

Dosage Form: Solution

Route: Intravenous

Strength: 27 mCi/mL

Recommended Study: Request for waiver of in vivo bioequivalence study requirements

To qualify for a waiver from submitting an in vivo bioequivalence study on the basis that bioequivalence is self-evident under 21 CFR 320.22(b)(1), a generic Lutetium Lu-177 vipivotide tetraxetan intravenous solution product must be qualitatively (Q1)[1] and quantitatively (Q2)[2] the same as the reference listed drug (RLD).

An applicant may seek approval of a drug product intended for parenteral use that differs from the RLD in preservative, buffer, or antioxidant provided that the applicant identifies and characterizes the differences and provides information demonstrating that the differences do not affect the safety or efficacy of the proposed drug product.[3]

Document History: Recommended August 2023

Unique Agency Identifier: PSG_215833

[1] Q1 (Qualitative sameness) means that the test product uses the same inactive ingredient(s) as the RLD product.
[2] Q2 (Quantitative sameness) means that concentrations of the inactive ingredient(s) used in the test product are within ± 5% of those used in the RLD product.
[3] Refer to 21 CFR 314.94(a)(9)(iii) for product for parenteral use.